الفهرس 
Association of FOXP3 gene polymorphism & serum level of interleukin-35 with Multiple sclerosis
AbstractOnly 14 pages are availabe for public view
 |  | from | 135 |  |  |
| | | from | 135 | | |
Abstract
Objective: To assess the role of FOXP3 rs3761548 (-3279 C/A) gene polymorphism with respect to MS susceptibility in Egyptian patients and whether this genetic polymorphism is associated with clinical status and treatment. Also determination of IL-35 concentration in relation to different genotypes and in relation to degree of disability and treatment. Methods: 100 MS patients & 100 healthy subjects were tested for FOXP3 rs3761548 genotype by Taqman Real-Time PCR and IL-35 concentration was measured in their serum using ELISA.Results: The level of serum IL-35 was significantly higher in MS patients when compared with healthy control volunteers (p= <0.0001). Serum concentration of IL-35 was higher in treated patients than in untreated ones with marginal statistical significance (p= 0.084). The frequency of distribution of FOXP3 (C/A) polymorphism genotypes and alleles was of no statistically significant difference between patients and healthy control subjects although there is increased expression of the mutant (A) allele among cases and increased expression of the wild (C) allele among control group (p= 0.261 and 0.307 respectively). No significant statistical difference was found between different FOXP3 genotypes of MS patients and age of the patient at onset of the disease, duration of the disease, number of relapses, receiving treatment, degree of disability (EDSS score), and first clinical presentation of the disease (p= 0.318, 0.383, 0.120, 0.738, 0.730, 0.475 respectively). Conclusion: The results of this study suggest that, FOXP3 rs3761548 polymorphism does not exhibit a significant influence on the susceptibility in MS patients. Nevertheless serum IL-35 level could be a sensitive marker of MS